Psychotomimesis Mediated by κ Opiate Receptors
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The κ opioid agonists are analgesics that seem to be free of undesired morphine-like effects. Their dysphoric actions observed with the κ agonist cyclazocine are thought to be mediated by an action at σ-phencyclidine receptors. The benzomorphan κ agonist MR 2033 is inactive at σ-phencyclidine receptors. In male subjects, the opiate-active (-)-isomer, but not the (+)-isomer, elicited dose-dependent dysphoric and psychotomimetic effects that were antagonized by naloxone. Thus, κ opiate receptors seem to mediate psychotomimetic effects. In view of the euphorigenic properties of μ agonists, our results imply the existence of opposed opioid systems affecting emotional and perceptual experiences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“agonism of κ-opioid receptors were shown to produce depression-like symptoms in humans (Pfeiffer et al., 1986).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Pfeiffer et al., 1986
In the citing paper
“Nonetheless, the three receptor types have different behavioral domains, with MOR and DOR mediating generally positive motivation and affect, while KOR mediates generally negative motivation and aversion (Pfeiffer et al 1986; Shippenberg et al 1987; Pecina and Berridge 2000; McLaughlin et al 2003; for reviews see Van Ree et al 2000; Le Merrer et al 2009).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Pfeiffer et al 1986
In the citing paper
“Kappa receptor agonists induce anxiogenic and dysphoric effects in humans (141-143) and depressive-like behavior in animals (i.e., increased immobility in the forced swim test) (144, 145).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [141]
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 748
Martin, W. R. (1983) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06637-2 · Cited by 648
Thrills in response to music and other stimuli
Goldstein, A. (1980) · Physiological Psychology · doi:10.3758/bf03326460 · Cited by 522
Mucha, R. F., & Herz, A. (1985) · Psychopharmacology · doi:10.1007/bf00432213 · Cited by 510
Self-citationThe binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00495865 · Cited by 509
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Opiate receptor binding sites in human brain
Pfeiffer, A., Pasi, A., Mehraein, P., & Herz, A. (1982) · Brain Research · doi:10.1016/0006-8993(82)91150-7 · Cited by 298
Self-citationPhencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film.
Quirion, R., Hammer, R. P., Herkenham, M., & Pert, C. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5881 · Cited by 254
Research works printed but not linked: 6
- Jasinski, D. R., Drug Addiction 1: 216 (1977).
- MARTIN, W.R., PHARMACOL REV 35: 283 (1984).
- MARTIN, W.R., SUBSTANCE AND ALCOHOL ACTIONS/MISUSE 1: 269 (1980).
- Shearman, G. T., Drug Discrimination: Application in CNS Pharmacology: 37 (1982).
- VAUPEL, D.B., FAILURE OF NALTREXONE (NTX) TO ANTAGONIZE PHENCYCLIDINE (PCP) AND THE OPIOID SKF-10047 (SKF) IN THE DOG, FEDERATION PROCEEDINGS 41: 1333 (1982).
- Zerssen, D. V., Assessment of Depression: 270 (1985).
Cited by
Items 301–400 of 956
Biased agonism at kappa opioid receptors: Implication in pain and mood disorders
Dogra, S., & Yadav, P. N. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.07.018 · Cited by 53
Comparison of opioid receptor distributions in the rat central nervous system
Gray, A. C., Coupar, I. M., & White, P. J. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.02.021 · Cited by 53
Sufka, K. J., Loria, M. J., Lewellyn, K., Zjawiony, J. K., Ali, Z., Abe, N., & Khan, I. A. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.10.059 · Cited by 52
Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity
Peters, M. F., Zacco, A., Gordon, J. C., Maciag, C. M., Litwin, L. C., Thompson, C., Schroeder, P. E., Sygowski, L. A., Piser, T. M., & Brugel, T. A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.017 · Cited by 51
GENETIC STUDY: Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence
Williams, T. J., LaForge, K. S., Gordon, D., Bart, G., Kellogg, S., Ott, J., & Kreek, M. J. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00069.x · Cited by 48
Structural Insights Accelerate the Discovery of Opioid Alternatives
Che, T., & Roth, B. L. (2021) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061620-044044 · Cited by 51
Wee, S., Vendruscolo, L. F., Misra, K. K., Schlosburg, J. E., & Koob, G. F. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003948 · Cited by 49
The Pharmacology of the Novel and Selective Sigma Ligand, PD 144418
Akunne, H. C., Whetzel, S. Z., Wiley, J. N., Corbin, A., Ninteman, F. W., Tecle, H., PEI, Y., Pugsley, T. A., & Heffner, T. G. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00161-x · Cited by 51
Kappa Opioids, Salvinorin A and Major Depressive Disorder
T. Taylor, G., & Manzella, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150727220944 · Cited by 44
Huang, P., Steplock, D., Weinman, E. J., Hall, R. A., Ding, Z., Li, J., Wang, Y., & Liu‐Chen, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313366200 · Cited by 50
Valenza, M., Butelman, E. R., & Kreek, M. J. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4647-0 · Cited by 49
Pilapil, C., Welner, S. A., Magnan, J., Gauthier, S. G., & Quirion, R. (1987) · Brain Research Bulletin · doi:10.1016/0361-9230(87)90080-3 · Cited by 49
Common Mechanisms Underlying Epileptogenesis and the Comorbidities of Epilepsy
Mazarati, A. M., & Sankar, R. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022798 · Cited by 48
Kivell, B. M., Paton, K. F., Kumar, N., Morani, A. S., Culverhouse, A., Shepherd, A. L., Welsh, S. A., Biggerstaff, A., Crowley, R. S., & Prisinzano, T. E. (2018) · Molecules · doi:10.3390/molecules23102602 · Cited by 48
Karpyak, V. M., Winham, S. J., Preuss, U. W., Zill, P., Cunningham, J. M., Walker, D. L., Lewis, K. A., Geske, J. R., Colby, C. L., Abulseoud, O. A., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001137 · Cited by 47
Sangalli, B. C. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00011-7 · Cited by 47
Zhu, J., Luo, L.-Y., Mao, G.-F., Ashby, B., & Liu‐Chen, L. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37361-6 · Cited by 47
Sex Differences in the Effects of a Kappa Opioid Receptor Antagonist in the Forced Swim Test
Laman-Maharg, A., Williams, A. V., Zufelt, M. D., Minie, V. A., Ramos-Maciel, S., Hao, R., Sanchez, E. O., Copeland, T., Silverman, J. L., Leigh, A., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00093 · Cited by 46
G protein signaling–biased agonism at the κ-opioid receptor is maintained in striatal neurons
Ho, J., Stahl, E. L., Schmid, C. L., Scarry, S. M., Aubé, J., & Bohn, L. (2018) · Science Signaling · doi:10.1126/scisignal.aar4309 · Cited by 46
DiMattio, K. M., Ehlert, F. J., & Liu‐Chen, L. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.054 · Cited by 46
Butelman, E. R., Rus, S., Prisinzano, T. E., & Kreek, M. J. (2010) · Psychopharmacology · doi:10.1007/s00213-009-1771-5 · Cited by 46
Drug withdrawal conceptualized as a stressor
Chartoff, E. H., & Carlezon, W. A. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000080 · Cited by 46
Zan, G., Wang, Q., Wang, Y., Liu, Y., Hang, A., Shu, X. H., & Liu, J. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.05.053 · Cited by 45
Peripheral Opioid Modulation of Visceral Paina
Gebhart, G. F., Su, X., Joshi, S. K., Ozaki, N., & Sengupta, J. N. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06675.x · Cited by 45
Anxiety and Its Therapy: Today and Tomorrow
Nutt, D. J. (1991) · doi:10.1007/978-1-349-11847-2_1 · Cited by 45
Ko, M., Butelman, E. R., & Woods, J. H. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38146-7 · Cited by 45
Carroll, F. I., Harris, L. S., & Aceto, M. D. G. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.09.013 · Cited by 44
Salvia divinorum use and phenomenology: results from an online survey
Sumnall, H. R., Measham, F. C., Brandt, S. D., & Cole, J. C. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110385596 · Cited by 44
Analysis of the Psychoactive Terpenoid Salvinorin A Content in Five Salvia divinorum Herbal Products
Wolowich, W. R., Perkins, A. M., & Cienki, J. J. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.9.1268 · Cited by 44
Behavioral effects of short-term administration of lithium and valproic acid in rats
Tomasiewicz, H. C., Mague, S. D., Cohen, B. M., & Carlezon, W. A. (2006) · Brain Research · doi:10.1016/j.brainres.2006.03.102 · Cited by 44
Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients
Heikkilä, L., Rimón, R., & Ternius, L. (1990) · Psychiatry Research · doi:10.1016/0165-1781(90)90001-l · Cited by 44
Peripheral and central antinociceptive actions of ethylketocyclazocine in the formalin test
Abbott, F. V. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90839-4 · Cited by 44
The impact of sex as a biological variable in the search for novel antidepressants
Williams, A. V., & Trainor, B. C. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.05.003 · Cited by 40
Saving Science Through Replication Studies
Edlund, J. E., Cuccolo, K., Irgens, M. S., Wagge, J., & Zlokovich, M. S. (2021) · Perspectives on Psychological Science · doi:10.1177/1745691620984385 · Cited by 43
Treating Chronic Pain with Buprenorphine—The Practical Guide
Case, A. A., Kullgren, J. G., Anwar, S., Pedraza, S. L., & Davis, M. P. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00910-8 · Cited by 43
Marinelli, M., Barrot, M., Simon, H., Oberlander, C., Dekeyne, A., Moal, M. L., & Piazza, P. V. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00340.x · Cited by 40
Probuphine® (buprenorphine implant): a promising candidate in opioid dependence
Barnwal, P., Das, S., Mondal, S., Ramasamy, A., Maiti, T., & Saha, A. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316681984 · Cited by 42
Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats
Page, S., Mavrikaki, M., Lintz, T., Puttick, D. J., Roberts, E., Rosen, H., Carroll, F. I., Carlezon, W. A., & Chartoff, E. H. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz054 · Cited by 42
Behavioral changes after maternal separation are reversed by chronic constant light treatment
Dimatelis, J. J., Stein, D. J., & Russell, V. A. (2012) · Brain Research · doi:10.1016/j.brainres.2012.07.013 · Cited by 39
Subcellular targeting of kappa‐opioid receptors in the rat nucleus locus coeruleus
Reyes, B. A. S., Chavkin, C., & van Bockstaele, E. J. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21880 · Cited by 37
Opioid peptide-derived analgesics
Schiller, P. W. (2005) · The AAPS Journal · doi:10.1208/aapsj070356 · Cited by 42
Dynorphin and prodynorphin mRNA changes in the striatum during nicotine withdrawal
Isola, R., Zhang, H., Tejwani, G. A., Neff, N. H., & Hadjiconstantinou, M. (2008) · Synapse · doi:10.1002/syn.20515 · Cited by 38
Trifilieff, P., & Martínez, D. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00044 · Cited by 41
Akaberi, M., Iranshahi, M., & Mehri, S. (2016) · Phytotherapy Research · doi:10.1002/ptr.5599 · Cited by 41
Kappa Opioid Receptor Activation Disrupts Prepulse Inhibition of the Acoustic Startle in Rats
Bortolato, M., Aru, G. N., Frau, R., Orrù, M., Fà, M., Manunta, M., Puddu, M., Mereu, G., & Gessa, G. L. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.030 · Cited by 41
Jansen (1997) · The Journal of near-death studies · doi:10.17514/jnds-1997-16-1-p5-26 · Cited by 41
Lindström, L. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00201-n · Cited by 41
Przewłocka, B., Turchan-Cholewo, J. T., Lasoń, W., & Przewłocki, R. (1996) · Neuroscience · doi:10.1016/s0306-4522(96)83012-0 · Cited by 41
Oeltgen, P. R., Welborn, J. R., Nuchols, P. A., Spurrier, W. A., Bruce, D. S., & Su, T. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90529-7 · Cited by 41
Deji, C., Yan, P., Ji, Y., Yan, X., Feng, Y., Liu, J., Liu, Y., Wei, S., Zhu, Y., & Lai, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.894886 · Cited by 40
Revisiting Oxycodone Analgesia
Ruan, X., Mancuso, K. F., & Kaye, A. D. (2017) · Anesthesiology Clinics · doi:10.1016/j.anclin.2017.01.022 · Cited by 40
Dezocine Alleviates Morphine-Induced Dependence in Rats
Wu, F., Babazada, H., Gao, H., Huang, X., Xi, C., Chen, C., Jin, X., Yu, W., & Liu, R. (2018) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000003365 · Cited by 40
Novel Targets to Treat Depression: Opioid-Based Therapeutics
Browne, C. A., Jacobson, M. L., & Lucki, I. (2020) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000242 · Cited by 40
Quirion, R., Pilapil, C., & Magnan, J. (1987) · Cellular and Molecular Neurobiology · doi:10.1007/bf00711306 · Cited by 40
Solecki, W., Ziolkowska, B., Krowka, T., Gieryk, A., Filip, M., & Przewlocki, R. (2009) · Brain Research · doi:10.1016/j.brainres.2008.12.002 · Cited by 39
Rorick‐Kehn, L. M., Witcher, J., Lowe, S. L., Gonzales, C., Weller, M. A., Bell, R. L., Hart, J. C., Need, A. B., McKinzie, J. H., Statnick, M. A., et al. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu036 · Cited by 39
The effects of butorphanol on locomotor activity in ponies: a preliminary study
Nolan, A. M., BESLEY, W., REID, J., & GRAY, G. (1994) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.1994.tb00253.x · Cited by 39
Paris, J. J., Reilley, K. J., & McLaughlin, J. P. (2012) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s4-007 · Cited by 39
The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research
Banks, M. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_268 · Cited by 39
Neurochemical Aspects of Addiction: Opioids and Other Drugs of Abuse
Herz, A., & Shippenberg, T. S. (1989) · Springer eBooks · doi:10.1007/978-1-4613-8817-3_4 · Cited by 39
Self-citationOlson, G. A., Olson, R. D., & Kastin, A. J. (1987) · Peptides · doi:10.1016/0196-9781(87)90147-1 · Cited by 39
Emery, M. A., & Eitan, S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.02.010 · Cited by 38
Yoo, J. H., Kitchen, I., & Bailey, A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01952.x · Cited by 38
The Kappa‐Opiate Receptor Impacts the Pathophysiology and Behavior of Substance Use
Mysels, D. J., & Sullivan, M. A. (2009) · American Journal on Addictions · doi:10.1080/10550490902925862 · Cited by 38
Analysis of natural product regulation of opioid receptors in the treatment of human disease
Badal, S. A. M., Turfus, S. C., Rajnarayanan, R. V., Wilson-Clarke, C. F., & Sandiford, S. L. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.021 · Cited by 38
Brice‐Tutt, A. C., Wilson, L., Eans, S. O., Stacy, H. M., Simons, C. A., Simpson, G. G., Coleman, J. S., Ferracane, M. J., Aldrich, J. V., & McLaughlin, J. P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15165 · Cited by 38
HZ2, a Selective Kappa‐Opioid Agonist
Kögel, B. Y., Christoph, T., Friderichs, E., Hennies, H. ‐., Matthiesen, T., Schneider, J., & Holzgrabe, U. (1998) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1998.tb00041.x · Cited by 38
Rothman, R. B., McLean, S., Bykov, V., Lessor, R. A., Jacobson, A. E., Rice, K. C., & Holaday, J. W. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90655-8 · Cited by 38
Functionality versus dimensionality in psychological taxonomies, and a puzzle of emotional valence
Trofimova, I. N. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0167 · Cited by 37
Cao, D., Huang, P., Chiu, Y.-T., Chen, C., Wang, H., Li, M., Zheng, Y., Ehlert, F. J., Zhang, Y., & Liu‐Chen, L. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00407 · Cited by 37
KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway
Estave, P. M., Spodnick, M. B., & Karkhanis, A. N. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_421 · Cited by 37
Limoges, A., Yarur, H. E., & Tejeda, H. A. (2022) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2022.963691 · Cited by 37
Pituitary adenylate cyclase-activating polypeptide induces a depressive-like phenotype in rats
Seiglie, M. P., Smith, K. L., Blasio, A., Cottone, P., & Sabino, V. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4045-4 · Cited by 37
Perlikowska, R., Piekielna‐Ciesielska, J., Gentilucci, L., Marco, R. D., Cerlesi, M. C., Calò, G., Artali, R., Tömböly, C., Kluczyk, A., & Janecka, A. E. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.012 · Cited by 37
Liu, H., Tian, Y., Ji, B., Lu, H., Xin, Q., Jiang, Y., Ding, L., Zhang, J., Chen, J., & Bai, B. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.07.009 · Cited by 37
Huskinson, S. L., Platt, D. M., Brasfield, M., Follett, M. E., Prisinzano, T. E., Blough, B. E., & Freeman, K. B. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05519-7 · Cited by 37
Zhou, L., Stahl, E. L., Lovell, K. M., Frankowski, K. J., Prisinzano, T. E., Aubé, J., & Bohn, L. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.001 · Cited by 37
Zhang, F., Li, J., Li, J.-G., & Liu‐Chen, L. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.3.1184 · Cited by 37
Distribution of opiate receptors within visual structures of the cat brain
Walker, J. M., Bowen, W. D., Thompson, L. A., Frascella, J., Lehmkuhle, S. W., & Hughes, H. C. (1988) · Experimental Brain Research · doi:10.1007/bf00406610 · Cited by 37
Kelsey, J. E., Verhaak, A. M. S., & Schierberl, K. C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.01.008 · Cited by 36
“[1–3]), binding of he endogenous dynorphin-like peptides to kappa-opioid recepors (KORs) produces dysphoric-, aversive-, and stress-like states in umans [4] and laboratory animals [5–7].”
BackgroundReinforcement principles for addiction medicine; from recreational drug use to psychiatric disorder
Edwards, S. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.005 · Cited by 36
Watson, S. J., Trujillo, K. A., Herman, J. P., & Akil, H. (1989) · Springer eBooks · doi:10.1007/978-1-4613-8817-3_2 · Cited by 36
EEG Spectral Analysis of the Neuroprotective Kappa Opioids Enadoline and PD117302
Tortella, F. C., Rose, J., Robles, L. E., Moreton, J. E., Hughes, J., & Hunter, J. C. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36761-8 · Cited by 36
Critical care sedation for neuroscience patients
Mirski, M. A., & Hemstreet, M. K. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.04.028 · Cited by 35
Dynorphin and κ-Opioid Receptor Dysregulation in the Dopaminergic Reward System of Human Alcoholics
Bazov, I., Sarkisyan, D., Kononenko, O., Watanabe, H., Yakovleva, T., Hansson, A. C., Sommer, W. H., Spanagel, R., & Bakalkin, G. Y. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0844-4 · Cited by 35
The effects of pentazocine, a kappa agonist, in patients with mania
Cohen, B. M., & Murphy, B. L. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008073 · Cited by 35
Individual and combined effects of ethanol and cocaine on intracellular signals and gene expression
Torres, G., & Horowitz, J. M. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(96)00034-6 · Cited by 35
Semisynthetic neoclerodanes as kappa opioid receptor probes
Lovell, K. M., Vasiljevik, T., Araya, J. J., Lozama, A., Prevatt‐Smith, K. M., Day, V. W., Dersch, C. M., Rothman, R. B., Butelman, E. R., Kreek, M. J., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.02.040 · Cited by 34
Abijo, T., Blum, K., & Gondré‐Lewis, M. C. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191118125702 · Cited by 34
Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain
Paton, K. F., Biggerstaff, A., Kaska, S., Crowley, R. S., Flamme, A. C. L., Prisinzano, T. E., & Kivell, B. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00765 · Cited by 34
Bertea, C. M., Luciano, P., Bossi, S., Leoni, F., Baiocchi, C., Medana, C., Azzolin, C. M. M., Temporale, G., Lombardozzi, M. A., & Maffei, M. E. (2006) · Phytochemistry · doi:10.1016/j.phytochem.2005.12.006 · Cited by 34
Tao, P., Hwang, C.-L., & Chen, C. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90553-3 · Cited by 34
Kappa opioid receptor signaling protects cartilage tissue against posttraumatic degeneration
Wu, L., Zhang, S., Shkhyan, R., Lee, S., Gullo, F., Eliasberg, C. D., Petrigliano, F. A., Ba, K., Wang, J., Lin, Y., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.88553 · Cited by 33
A single-vector intersectional AAV strategy for interrogating cellular diversity and brain function
Hughes, A. C., Pittman, B. G., Xu, B., Gammons, J. W., Webb, C. M., Nolen, H. G., Chapman, P., Bikoff, J. B., & Schwarz, L. A. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01659-7 · Cited by 33
Kappa opioid receptor binding in major depression: A pilot study
Miller, J. M., Zanderigo, F., Purushothaman, P. D., DeLorenzo, C., Rubin‐Falcone, H., Ogden, R. T., Keilp, J. G., Oquendo, M. A., Nabulsi, N., Huang, Y. H., et al. (2018) · Synapse · doi:10.1002/syn.22042 · Cited by 33
The effects of buprenorphine on fentanyl withdrawal in rats
Bruijnzeel, A. W., Marcinkiewcz, C. A., Isaac, S. K., Booth, M. M., Dennis, D. M., & Gold, M. S. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0670-2 · Cited by 33
Vig, B. S., Murray, T. F., & Aldrich, J. V. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0256023 · Cited by 33
Hughes, N., McKnight, A. T., Woodruff, G. N., Hill, M. P., Crossman, A. R., & Brotchie, J. M. (1998) · Movement Disorders · doi:10.1002/mds.870130206 · Cited by 33
Rothman, R. B., & McLean, S. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90016-9 · Cited by 33
van den Brink, W., & Kiefer, F. (2020) · doi:10.1093/med/9780198713005.003.0050 · Cited by 32
Metadata
- Authors
- Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M.
- Affiliations
- LMU Klinikum (DE)
- Boehringer Ingelheim (Germany) (DE)
- Max Planck Society (DE)
- Max Planck Institute of Psychiatry (DE)
- ORCID
- Pfeiffer, Andreas
- Venue
- Science
- Published
- 1986-08-15
- Volume
- 233
- Issue
- 4765
- Pages
- 774-776
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2032643119
- Cited by
- 857
- References
- 30
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 23 · 2023: 17 · 2022: 18 · 2021: 38 · 2020: 42 · 2019: 21 · 2018: 27 · 2017: 24 · 2016: 37 · 2015: 38 · 2014: 30 · 2013: 35 · 2012: 41
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psychotomimetic effects, kappa opioid receptor, kappa opioid receptor agonists, cyclazocine, naloxone antagonism, stereoisomers, mu-opioid receptor agonists, euphoria, analgesia
- MeSH terms
- Adult, Anxiety, Benzomorphans, Humans, Male, Middle Aged, Morphinans, Naloxone, Personality Tests, Phencyclidine, Receptors, Opioid, Receptors, Opioid, kappa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.